About: Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true?
Creator	Elmokadem, Ali Zaitoun, Mohamed Abd, Mohammad Basha, Alkhalik
Source	Medline; PMC
abstract	More than 1,200 active or recruiting clinical trials for novel coronavirus disease 2019 (COVID-19) treatments and vaccines are registered. Many drugs have shown promise for treatment of COVID-19. Nevertheless, up to date, no drugs have been confirmed as a definitive treatment for COVID-19. Trials such as the SOLIDARITY and RECOVERY are ongoing, and first results were announced in favour of therapy with dexamethasone with a significant trend showing greatest benefit among those patients requiring ventilation. The drawbacks of these trials include exposing the patients to drugs with well-documented systemic adverse effects or unknown complications of novel therapies without proof of clinical benefit. We present here the hypothesis that bronchial artery infusion could be an alternative for systemic drug infusion in COVID-19 trials with superadded benefits of high drug concentration and low systemic adverse effects. The concept of this idea has many uncertainties and no current clinical data to support. Perhaps, the technique should be first applied in animal models to determine its safety and calculate the effective dose of the drugs. Guidelines and reviews of pharmacotherapy for COVID-19 should be implemented for this fiction to come true.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1186/s41747-020-00171-4
bibo:pmid	32632766
has license	cc-by
sha1sum (hex)	5d2a0108bfc13fd46c8b0798bd15da8f87719e20
schema:url	https://doi.org/10.1186/s41747-020-00171-4
resource representing a document's title	Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true?
has PubMed Central identifier	PMC7338094
has PubMed identifier	32632766
schema:publication	Eur Radiol Exp
resource representing a document's body	covid:5d2a0108bfc13fd46c8b0798bd15da8f87719e20#body_text
is schema:about of	named entity 'More' named entity 'drugs' covid:arg/5d2a0108bfc13fd46c8b0798bd15da8f87719e20 named entity 'patients' named entity 'ongoing' named entity 'clinical trials' named entity 'drug' named entity 'drugs' named entity 'exposing' named entity 'bronchial artery' named entity 'promise' named entity 'drugs' named entity 'fiction' named entity 'clinical trials' named entity 'COVID-19' named entity 'COVID' named entity 'COVID' named entity 'COVID' named entity 'treatment options' named entity 'lopinavir' named entity 'WHO' named entity 'safe and effective' named entity 'ground-glass opacities' named entity 'immunomodulatory' named entity 'tumour' named entity 'antiviral' named entity 'controlled clinical trial' named entity 'severe acute respiratory syndrome coronavirus' named entity 'lung tumours' named entity 'steroid injection' named entity 'COVID' named entity 'pathophysiologic' named entity 'anti-inflammatory' named entity 'Wuhan' named entity 'vaccines' named entity 'COVID' named entity 'infection' named entity 'Ebola' named entity 'experimental animals' named entity 'SOLIDAR' named entity 'blood flow' named entity 'dexamethasone' named entity 'effective dose' named entity 'infection' named entity 'hydroxychloroquine' named entity 'lung' named entity 'human immunodeficiency virus' named entity 'anti-inflammatory' named entity 'first-pass effect' named entity 'clinical trials' named entity 'hepatic failure' named entity 'pharmacotherapy' named entity 'adverse effects' named entity 'COVID' named entity 'June 17' named entity 'bronchial artery' named entity 'pharmacotherapy' named entity 'COVID' named entity 'bronchial artery' named entity 'anticoagulant therapy' named entity 'drug delivery' named entity 'HIV' named entity 'bronchial artery' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'azithromycin' named entity 'COVID' named entity 'COVID' named entity 'global pandemic' named entity 'SOLIDARITY trial' named entity 'WHO' named entity 'China' named entity 'COVID-19' named entity 'World Health Organization' named entity 'infectious disease' named entity 'SOLIDARITY trial' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software